Idera Pharmaceuticals Inc. (NASDAQ:IDRA): First Quarter Net Loss Widened To $9.1 Million

846

Dallas, Texas 05/28/2014 (FINANCIALSTRENDS) – Idera Pharmaceuticals Inc. (NASDAQ:IDRA), a clinical stage company, recently reported its 1Q14 financial results for the quarter ended March 31, 2014. The company reported net loss of $9.1 million ($0.12 per diluted share), for 1Q14 as compared to a net loss of $4.1 million ($0.15 per diluted share) for the same prior year quarter. The company noted nominal revenues for both 1Q14 and 1Q13.

Idera Pharmaceuticals’ 1Q14 research and development expenses increased to $6.9 million as compared to $2.3 million for 1Q13. General and administrative expenses for 1Q14 increased to $2 million as compared to $1.5 million for 1Q13. The company reported cash and cash equivalents and investments of $70.6 million as at March 31, 2014 as compared to $35.6 million as at December 31, 2013. During 1Q14 the company also announced gross proceeds of $40.1 million from its underwritten public offering in February 2014.

Executive Affirmations

Chief Financial Officer of Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Lou Arcudi mentioned to have ended 1Q14 with a strong financial position, ensuring adequate resources to advance the company’s clinical and pre-clinical programs and meet its near term business objectives.

The Chief Executive Officer of the company, Sudhir Agrawal mentioned that company initiated clinical development for its IMO-8400 and the company looks forward to progress this candidate in clinical trials for its diffuse large B-cell lymphoma and Waldenstrom’s macroglobulinemia indications.

Management Strengthening

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) also strengthened its management team to better pursue clinical development of its pipeline portfolio. The company announced appointment of Lou Brenner as its SVP and Chief Medical Officer; Kate Haviland as VP for Rare Diseases; Nancy Wyant as VP for Clinical Operations; and Joe Lobacki as GM of Oncology, among others.

Stock Update

Yesterday, the stock of the company gained 3.56% and closed at $2.62. The stock has delivered 37.62% negative returns year to date.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.